ORMD-0801 From Wikipedia, the free encyclopedia Experimental drug ORMD-0801 is an experimental insulin analog that is taken by mouth, rather than injected. It is developed by Oramed Pharmaceuticals to treat diabetes.[1][2][3][4] ↑ Eldor, Roy; Arbit, Ehud; Corcos, Asher; Kidron, Miriam (9 April 2013). "Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study". PLOS ONE. 8 (4) e59524. Bibcode:2013PLoSO...859524E. doi:10.1371/journal.pone.0059524. ISSN 1932-6203. PMC 3622027. PMID 23593142. ↑ Eldor, Roy; Neutel, Joel; Homer, Kenneth; Kidron, Miriam (November 2021). "Efficacy and safety of 28-day treatment with oral insulin ( ORMD -0801) in patients with type 2 diabetes: A randomized, placebo-controlled trial". Diabetes, Obesity and Metabolism. 23 (11): 2529–2538. doi:10.1111/dom.14499. PMID 34310011. S2CID 236432013. ↑ Eldor, Roy; Fleming, G. Alexander; Neutel, Joel; Homer, Kenneth E.; Kidron, Miriam; Rosenstock, Julio (1 June 2020). "1004-P: Oral Insulin (ORMD-0801) Effects on Glucose Parameters in Uncontrolled T2DM on OADs". Diabetes. 69 (Supplement_1). doi:10.2337/db20-1004-P. S2CID 225845842. ↑ Eldor, Roy; Francis, Bruce H.; Fleming, Alexander; Neutel, Joel; Homer, Kenneth; Kidron, Miriam; Rosenstock, Julio (April 2023). "Oral insulin ( ORMD -0801) in type 2 diabetes mellitus: A dose-finding 12-week randomized placebo-controlled study". Diabetes, Obesity and Metabolism. 25 (4): 943–952. doi:10.1111/dom.14901. PMID 36281496. S2CID 253108516. Related Articles